Pharming Group N.V. (ENXTAM:PHARM) is looking for acquisitions. Jeroen Wakkerman, Chief Financial Officer said, "We continue to focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases in therapeutic areas like immunology, hematology, respiratory and gastroenterology, and that is to further leverage our commercial infrastructure globally".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 EUR | +2.16% | +2.16% | -12.71% |
Apr. 22 | Pharming Group to Buy Back EUR123 Million of Bonds due 2025 | MT |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.71% | 647M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Group Seeks Acquisitions